Zai Lab to raise about $250 million through a private placement of shares
Zai Lab will sell 11.34 million ADSs at $22.04 each in a PIPE worth about $250 million, with proceeds going to development of zoci.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Biopharmaceutical company Zai Lab, based in China and the United States, has agreed to sell 11.34 million American Depositary Shares (ADSs) at $22.04 apiece. Each ADS represents ten ordinary shares. According to TradingView, gross proceeds from the private investment in public equity (PIPE) are expected to be about $250 million before placement agent fees and other offering costs.
The closing is expected on or about October 27, 2026, subject to customary conditions. The company plans to use most of the net proceeds to support global development of zocilurtatug pelitecan (zoci), its DLL3-targeting antibody-drug conjugate. The financing is led by TCGX, with other participants including RA Capital Management and Wellington Management.
why it matters
The deal is small for the broader market, so its impact is limited, but it is a meaningful funding step for Zai Lab shares. PIPE deals often come with an obligation to register resale of the ADSs, which can add supply of the stock once the registration takes effect.
tags
instruments
sources
- Zai Lab Announces $250 Million Private Placement — TradingView, 23 October 2026 at 00:52 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗